wrong Akki:
Teva made a big mistake by returning ATL1102..
Fda has already approved P2b for Ms at a lower dose and given the results from the DMD trial the FDA will grant a higher dose . There will be more interest from Pharma re Ms because of the success of the DMD trial.
Asthma: Human trials will begin given the success with mice...Anp didn’t have the finance but soon they will:.
so you see Akki Anp has 3 drugs with multiple indications and Not just a one horse pony..
ANP “not a one trick Pony”, page-4
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.4¢ |
Change
-0.001(1.18%) |
Mkt cap ! $75.73M | |||
| Open | High | Low | Value | Volume |
| 8.9¢ | 8.9¢ | 8.2¢ | $63.67K | 761.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 43210 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.7¢ | 200 | 1 |
View Market Depth
| Last trade - 15.59pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
8.4¢ |
Change
-0.001 ( 3.45 %) |
||||
| Open | High | Low | Volume | ||
| 8.9¢ | 8.9¢ | 8.2¢ | 115933 | ||
| Last updated 14.43pm 07/06/2024 ? | |||||
| PER (ASX) Chart |